U.S., June 18 -- ClinicalTrials.gov registry received information related to the study (NCT07024238) titled 'Impact of SCFA Supplementation on Gut Microbiome Composition of Kidney Transplant Recipients' on April 22.
Brief Summary: This is a randomized, double-blind, placebo-controlled clinical trial designed to evaluate the effects of high-dose short-chain fatty acid (SCFA) supplementation on the gut microbiome and host metabolome in stable kidney transplant recipients. Participants will be randomly assigned to receive either 1000 mg of sodium butyrate per day or placebo for a duration of 12 weeks. Comprehensive profiling of the serum and urinary metabolome, along with analysis of the gut microbiome composition and diversity, will be condu...